Menu

Walgreens Sues Theranos for $140 Million

The drugstore giant is accusing the blood-testing company of breach of contract, although the full details of the suit have not been disclosed.

Nov 10, 2016
Joshua A. Krisch

In another blow to Theranos, the Silicon Valley startup that closed its blood-testing labs and fired hundreds of employees in 2015 following federal investigations into its practices, one of the company’s erstwhile partners, Walgreens, has initiated a $140 million lawsuit, The Wall Street Journal reported. The complaint was filed under seal, so details remain scant, but Walgreens confirmed that a suit against Theranos is pending.

The relationship between Walgreens and Theranos began in 2013, with Walgreens agreeing to use Theranos’s blood-testing technology in 40 of its Arizona locations. When the Theranos probe came to light, Walgreens pulled all 40 testing sites from its locations.

Theranos released a statement on November 8 that vigorously denied any wrongdoing, and placed the blame squarely on the drugstore giant. “Over the years, Walgreens consistently failed to meet its commitments to Theranos,” the startup wrote. “Through its mishandling of our partnership and now this lawsuit, Walgreens has caused Theranos and its investors significant harm.” 

July 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

IDT and Washington University join forces to increase access to the latest NGS technologies
IDT and Washington University join forces to increase access to the latest NGS technologies
As part of its commitment to advocate for the genomics age, Integrated DNA Technologies (IDT) aims to lower the barriers to access the latest NGS technologies.
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) July 15, 2019 announced the launch of its Bio-Plex Pro Human Immunotherapy Panel 20-plex, a multiplex immunoassay that offers a targeted approach for Immunotherapy Research.
DeNovoMAX - NRGene's new genomics tool to meet a major agbio need:
DeNovoMAX - NRGene's new genomics tool to meet a major agbio need:
NRGene has launched a new product that aims to empower breeding and maximize agricultural yield as part of the Denovo assembly product suite offered by the company.
Overcoming the Efficiency Challenge in Clinical NGS
Overcoming the Efficiency Challenge in Clinical NGS
Download this white paper to see how an ECS lab serving a network of more than 10,000 healthcare providers integrated QIAGEN Clinical Insight (QCI) Interpret to significantly reduce manual variant curation efforts and increase workflow efficiency by 80%!